Technical Analysis for VIR - Vir Biotechnology, Inc.

Grade Last Price % Change Price Change
grade C 17.38 1.88% 0.32
VIR closed up 1.88 percent on Friday, February 14, 2020, on 86 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Down
Historical VIR trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 1.88%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.88%
Stochastic Reached Oversold Weakness 1.88%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license and option agreement Visterra, Inc.; and license agreement with The Rockefeller University and MedImmune, Inc. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.
Biotechnology Therapeutic Products Astrazeneca Alnylam Pharmaceuticals Therapeutic Tuberculosis Pharmaceutical Companies Medimmune Rockefeller University Serious Infectious Diseases Treatment Of Hepatitis B

Is VIR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 27.5
52 Week Low 11.65
Average Volume 322,250
200-Day Moving Average 0.00
50-Day Moving Average 15.79
20-Day Moving Average 20.00
10-Day Moving Average 19.65
Average True Range 2.20
ADX 31.0
+DI 20.20
-DI 23.18
Chandelier Exit (Long, 3 ATRs ) 20.91
Chandelier Exit (Short, 3 ATRs ) 20.84
Upper Bollinger Band 25.43
Lower Bollinger Band 14.57
Percent B (%b) 0.26
BandWidth 54.32
MACD Line 0.73
MACD Signal Line 1.48
MACD Histogram -0.753
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.94
Resistance 3 (R3) 19.02 18.59 18.68
Resistance 2 (R2) 18.59 18.19 18.55 18.59
Resistance 1 (R1) 17.98 17.94 18.29 17.90 18.51
Pivot Point 17.55 17.55 17.70 17.51 17.55
Support 1 (S1) 16.94 17.15 17.25 16.86 16.25
Support 2 (S2) 16.51 16.90 16.47 16.17
Support 3 (S3) 15.90 16.51 16.08
Support 4 (S4) 15.82